Pharmaceutical News

RSS

Quest receives U.S. patent allowance for cancer combination therapy

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has received notice of allowance for U.S. Patent Application 10/831,886 entitled: "Combination Therapy for Treating Disease".

22 Jul 2011

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of REMICADE for the treatment of moderately to severely active ulcerative colitis in pediatric patients who have had an inadequate response to conventional therapy.

22 Jul 2011

FDA approves Cephalon's REMS for FENTORA, ACTIQ

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the Risk Evaluation and Mitigation Strategy (REMS) for FENTORA and ACTIQ.

22 Jul 2011

A*STAR's ETC, Agilent introduce drug screening platform

Agilent Technologies Inc. and A*STAR's Experimental Therapeutics Centre (ETC) today announced the launch of a drug screening platform within ETC's new Singapore Screening Centre.

22 Jul 2011

Adamis receives U.S. patent for APC-100 to treat prostate cancer

Adamis Pharmaceuticals Corporation, today announced the technology which constitutes its compound APC-100 was recently granted a patent in the United States.

22 Jul 2011

FDA approves Boca Pharmacal's Hydrocodone Bitartrate and Acetaminophen Oral Solution ANDA

Boca Pharmacal, Inc., today announced that it has received approval from the FDA of its Abbreviated New Drug Application (ANDA) for Hydrocodone Bitartrate and Acetaminophen Oral Solution, 7.5mg / 325mg per 5mL, the generic version of Hycet Oral Solution distributed by FSC Laboratories, Inc.

22 Jul 2011

EMA says link between narcolepsy and Pandemrix 2009 H1N1 vaccine exists

A final review result from Europe's drug regulatory agency released a positive link between narcolepsy and the Pandemrix 2009 H1N1 vaccine. The agency recommends a labeling change that limits the vaccine's use in children and teens to when protection is needed and seasonal trivalent vaccine isn't available.

21 Jul 2011

High cost of multiple sclerosis drugs

According to a study released this Wednesday, drugs used in the hope of slowing multiple sclerosis progression may help some patients, but at a very high cost.

21 Jul 2011

Australian anti-cancer company completes $2.6 million placement

Australian monoclonal antibody company, Immune System Therapeutics Limited (IST), today said it completed a private placement to raise $2 million from new and existing private and institutional investors in Australia. Investors have agreed to purchase 5,200,000 shares in the company at a price of $0.50 cents per share resulting in gross proceeds of $2.6 million.

21 Jul 2011

Randox win Premier Healthcare Alliance contract for Quality Control

Randox Laboratories Ltd is proud to announce that in April 2011 we signed a multi-year agreement with the Premier Healthcare Alliance for the supply of Acusera Quality Control (QC) materials. The agreement will provide the 90,000 plus Premier members with access to our extensive range of quality control products and the benefits they offer clinical laboratories. When asked about the new agreement Laura Coyle Randox Business Manager for the USA revealed that ‘We look forward to strengthening our relationship with Premier and providing added value to their members’.

From Randox Laboratories Ltd. 21 Jul 2011

Alliqua acquires global license for wound care dressings from Noble Biomaterials

Alliqua, Inc., an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and wound care technologies today announced that it has acquired from Noble Biomaterials, Inc. a 10 year exclusive global license for two wound care dressings, with an additional 10 year renewal option.

21 Jul 2011

Excess brain activity in aMCI patients contributes to brain dysfunction underlying memory loss

An existing anti-seizure drug improves memory and brain function in adults with a form of cognitive impairment that often leads to full-blown Alzheimer's disease, a Johns Hopkins University study has found.

21 Jul 2011

Caltech, Zcube collaboration will bring painless transdermal drug delivery to patients

Zcube Srl, a research venture of the Italian pharmaceutical company Zambon, and the California Institute of Technology (Caltech) have signed an exclusive research and option agreement to develop and commercialize skin patches that contain embedded carbon nanotubes for delivering drugs. The patches will first be developed to painlessly administer drugs through the skin; other applications are envisioned for future use. Mory Gharib, Hans W. Liepmann Professor of Aeronautics and professor of bioinspired engineering, is the principal investigator at Caltech.

21 Jul 2011

Study examines cost-effectiveness of MS drugs in the U.S.

A new study examining the cost-effectiveness of drugs to treat multiple sclerosis (MS) in the United States finds that the health gains from these drugs come at a very high cost compared to basic therapy to control the symptoms of MS and compared to treatments for other chronic diseases.

21 Jul 2011

China BCT to launch 21 new retail pharmacy stores in Guangxi

China BCT Pharmacy Group, Inc., a leading pharmaceutical distributor, retail pharmacy, and manufacturer of pharmaceutical products in Guangxi Province, China, today announced that the Company is in the process of launching 21 new retail pharmacy stores in Guangxi, bringing the total number of "Baicaotang" branded stores to 208.

21 Jul 2011

Roche, Merck sign new non-exclusive agreement for HCV triple combination therapy

Merck, known as MSD outside the United States and Canada, announced today that it has signed a new non-exclusive agreement with Roche, through the companies' respective subsidiaries, for the global promotion, upon appropriate marketing approvals, of VICTRELIS (boceprevir) as part of a triple combination therapy regimen with peginterferon alfa and ribavirin.

21 Jul 2011

Pharmaceutical News

Quest receives U.S. patent allowance for cancer combination therapy

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

FDA approves Cephalon's REMS for FENTORA, ACTIQ

A*STAR's ETC, Agilent introduce drug screening platform

Adamis receives U.S. patent for APC-100 to treat prostate cancer

FDA approves Boca Pharmacal's Hydrocodone Bitartrate and Acetaminophen Oral Solution ANDA

EMA says link between narcolepsy and Pandemrix 2009 H1N1 vaccine exists

High cost of multiple sclerosis drugs

Australian anti-cancer company completes $2.6 million placement

Randox win Premier Healthcare Alliance contract for Quality Control

Alliqua acquires global license for wound care dressings from Noble Biomaterials

Excess brain activity in aMCI patients contributes to brain dysfunction underlying memory loss

Caltech, Zcube collaboration will bring painless transdermal drug delivery to patients

Study examines cost-effectiveness of MS drugs in the U.S.

China BCT to launch 21 new retail pharmacy stores in Guangxi

Roche, Merck sign new non-exclusive agreement for HCV triple combination therapy

FDA approves Brilinta to reduce cardiovascular death and heart attack in ACS patients

USPTO issues patent for Mirna's tumor suppressor microRNAs

Adamis' APC-300 inhibits growth of prostate cancer cells

Novel vaccine for treating heroin addiction

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News